Pasithea therapeutics to present updated data from ongoing phase 1 trial of pas-004 in advanced cancer patients at the 2025 asco annual meeting

Miami, april 24, 2025 (globe newswire) -- pasithea therapeutics corp. (nasdaq: ktta) (“pasithea” or the “company”), a clinical-stage biotechnology company developing pas-004, a next-generation macrocyclic mek inhibitor, for the treatment of neurofibromatosis type 1 (nf1) and other mapk pathway driven indications, today announced the acceptance of an abstract for a poster prenstation at the annual meeting of the american society for clinical oncology (asco) taking place may 30 – june 3, 2025, in chicago, illinois. the company will present updated interim clinical data from its onging phase 1 clinical trial of pas-004 in patients with mapk pathway driven advanced solid tumors.
KTTA Ratings Summary
KTTA Quant Ranking